Sentigen Announces Issuance Of Patent
Published: Jun 14, 2006
PHILLIPSBURG, N.J.--(BUSINESS WIRE)--June 14, 2006--SENTIGEN HOLDING CORP. (Nasdaq: SGHL - News) today announced the issuance of U.S. Patent No. 7,045,281 entitled "Method for Using Division Arrested Cells in Screening Assays," covering the generation and application of Division Arrested Assay Ready Cells(TM) in drug discovery. This technology was developed by Sentigen Holding Corp.'s wholly-owned subsidiary, Cell & Molecular Technologies Inc., to improve the quality and consistency of cellular assays used in drug screening. The use of Division Arrested Assay Ready Cells(TM) has been demonstrated in GPCR assays, ion channel assays, receptor tyrosine kinase assays, reporter assays, high content imaging assays, and cell apoptosis assays, and has been the subject of a number of recent peer reviewed scientific journal articles.